Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating ...

Gone are the days when parents searched for scribbled circles in catalogues to decipher their kids’ wish lists. These days, tweens and teens — mostly girls — aren’t even using Pinterest or their Notes ...

Christopher Wiggins is the politics and news editor at equalpride, where he leads and shapes coverage across The Advocate, Out, and Them. Based in Washington, D.C., he oversees national reporting on ...

Not every sales pitch for a reverse mortgage is worth your time. Retirees are the target demographic for reverse mortgages — a tool that can tap their home’s equity for cash. But it's important to be ...

When it comes to being happier, we often look to the future — what we can change about our lives, our relationships and our upcoming contributions. But it’s worth reflecting on the moments that have ...

Christopher Winrow, PhD, Recursion’s vice president of neuroscience, inside the company’s lab. Recursion marked a milestone in its up to $12 billion artificial intelligence (AI) collaboration with ...

Crypto exchanges are rapidly expanding into traditional finance by offering perpetual futures tied to stocks, indexes and commodities, with trading volume surging to $1.32 trillion in the first five ...

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...

Add Yahoo as a preferred source to see more of our stories on Google. But as Harvard University happiness researcher Arthur C. Brooks has found, in his studies as well as his own experience, that ...

In the brief history of AI security, the prompt injection has quickly become the top threat. Large language models are inherently unable to distinguish between legitimate instructions provided by ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...